The study and its comparison
Fifty women over thirty with high-risk HPV persisting for more than two years were randomized to AHCC or placebo. Forty-one completed the study. The AHCC arm received six months of the extract followed by placebo. [1]
Fourteen of twenty-two AHCC completers tested negative at six months; nine of those fourteen remained negative six months after stopping. Two of nineteen placebo completers were negative at twelve months. [1]
What the finding establishes
These are small completer denominators with different reported assessment times, not a guaranteed clearance rate. Viral-test negativity is not a cancer endpoint. Later unblinded crossover results are not another randomized comparison. One author disclosed earlier Amino Up research grants; complete current funding was not established from the abstract. Screening and follow-up remain separate clinical needs. [1]
A hypothetical distinction
Imagine nine durable responses are reported among fourteen initial responders. That is not nine of every fourteen randomized patients.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- AHCC ® Supplementation to Support Immune Function to Clear Persistent Human Papillomavirus Infections.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.